In your Trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months? Please use the latest 6 months of data that you can provide.
Please provide the number of patients by treatment for the following disease modifying drugs.
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Ampyra (Fampyra)
Peginterferon beta-1a (Plegridy)
Daclizumab (Zinbryta)
Others

Download response MS treatment Sept 2016 РFeb 2017. 240317